




IMPACT BIOMEDICAL, INC.

NEW SOLUTIONS IN HUMAN HEALTH AND WELLNESS





SAFE HARBOR

This presentation contains certain forward-looking statements within the meaning of the federal securities laws. These statements may be made a part of this presentation or by reference to other documents we file with the SEC.

Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,” “may,” “estimate,” “should,” “seek,” “expect,” “plan,” “believe,” “intend,” and similar words, or the negatives of those words, are intended to identify forward-looking statements. Certain statements regarding the following particularly are forward-looking in nature: Future financial performance, market forecasts or projections, projected capital expenditures, our business strategy.

All forward-looking statements are based on our management’s beliefs, assumptions, and expectations of our future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause our actual results, performance, or financial condition to be materially different from the expectations of future results, performance, or financial position. Our actual results may differ materially from the results discussed in forward-looking statements. Factors that might cause such a difference include, but are not limited to, the risks set forth in “Risk Factors” included in our SEC filings.

The specific discussions contained in this presentation about our company include financial projections as well as future estimates and expectations about our company’s business. The projections, estimates, and expectations are presented in this presentation only as a guide about future possibilities and do not represent actual amounts or assured events. All the projections and estimates are based exclusively on our company management team’s own assessment of its business, the industry in which it works, and the economy at large. Additionally, other operational factors, including capital resources and liquidity, financial condition, fulfillment of contracts and opportunities are also based on an assessment. The actual results may differ significantly from the projections. Potential shareholders should not make an investment decision based solely on our company’s projections, estimates, or expectations.



EXECUTIVE SUMMARY

Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.

Core Technologies Intellectual Property (IP) *Eight (8) Patents Issued (Exp 2029-2040) and 40+ Patents Pending*

Biotech/Med-Tech (FDA/EMA Regulated)	Consumer Wellness/OTC	Emerging Technology
<ul style="list-style-type: none"> ● Linebacker Biopharmaceuticals for monotherapy and combination therapy for inflammatory disease, oncology and neurology ● Laetose™ Pharmaceuticals for anti-inflammatory and metabolic diseases. 	<ul style="list-style-type: none"> ● Equivir™ /G (Flavonoids): OTC Anti-viral Treatments ● 3F (Functional Fragrance): Natural Insect Repellent ● 3F Antimicrobial Treatments ● Laetose Sugar Substitute/Diet Supplement 	<ul style="list-style-type: none"> ● Bioplastics ● Natural Preservatives ● Biopharmaceuticals ● Other

Investment Opportunity

- \$5-10MM IPO Offering
- Use of Proceeds: Research and development, acquisitions, working capital, and other general corporate purposes.

Team & Leadership

- Significant Experience Developing New Healthcare Offerings in Private and Public Companies
- Proven Business Model in Discovery, Confirmation, and Monetization of Assets
- Existing License/Revenue Agreements and R&D Network



IMPACT BIOMEDICAL, INC.

CORE TECHNOLOGIES



LINEBACKER

LineBacker is a platform electrophilically enhanced polyphenols to induce potency, efficacy, and bioavailability, without compromising safety standards.



EQUIVIR

Equivir technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols that have demonstrated antiviral effects with additional potential applications such as medication or supplements.



3F

3F (Functional Fragrance Formulation) is a unique formulation of specialized ingredients (e.g., terpenes) from botanical sources with potential application as an insect repellent and an antimicrobial.



LAETOSE

Unique combination of multiple sugars independently with inositol, with potential to inhibit the inflammatory and metabolic response of sugar alone.



LINEBACKER

APPLICATIONS / INDICATION



LUNG CANCER

Monotherapy and/or combination therapy.



COLON CANCER

Monotherapy and/or combination therapy.



OTHER APPLICATIONS

Neurology.




IMPACT BIOMEDICAL, INC.

LINEBACKER (LB)

Modified Myricetin, a plant derived flavonoid that exhibits strong antioxidant, anti-cancer, anti-diabetic, and anti-inflammatory activities.

THERAPEUTIC POTENTIAL*



DEVELOPMENT / IP

- **LB-1: Potential Co-therapy (Colon/Lung):**
 - Down regulates PIM (proviral integration site for moloney murine leukemia virus) kinase receptors.
- **Composition and Method Patents**
 - Inflammatory Diseases/Expires May 2036/2037
 - Neurological disorders/Expires May 2029

COMMERCIAL & MARKET POTENTIAL

- Lung cancer is leading cause of cancer deaths worldwide: [Lung cancer \(who.int\)](http://who.int)
- Colon cancer is the second leading cause of cancer deaths worldwide: [Colorectal cancer \(who.int\)](http://who.int).

DEVELOPMENT PARTNERS

- **ProPhase Labs (NASDAQ: PRPH):**
- Global Development & Commercialization Partner: Oncology, Neurology, Inflammatory Disease
- Pre-clinical studies ongoing

* Source: ResearchGate



EQUIVIR™ /G (FLAVONOIDS)

- Two Discreet Products With Novel blend of generally recognized as safe (GRAS) polyphenols.
- Polyphenol blend:
 - Myricetin
 - Hesperitin
 - Piperine
 - Gallic Acid

APPLICATIONS / INDICATION



OTC Medication Supplement



RX Applications

NATURALLY-SOURCED ORIGIN



Myricetin

vegetables, nuts, berries, and tea



Hesperitin

citrus fruits



Piperine

black pepper

DEVELOPMENT / IP

Composition and Method Patents

- Antiviral Infections/Expires Dec 2036.
- Antiviral Infections/Expires Aug 2037.

COMMERCIAL & MARKET POTENTIAL

- 17.2 billion upper respiratory tract infections worldwide in 2019: Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019 - eClinicalMedicine (thelancet.com)

DEVELOPMENT PARTNERS

- **ProPhase Labs (NASDAQ: PRPH)**
- Global Development & Commercialization Partner: Antiviral, Health Supplement, Pharmaceuticals



IMPACT BIOMEDICAL, INC.



3F

3F FUNCTIONAL FRAGRANCES

- Suite of “functional fragrances” containing specialized botanical ingredients (e.g., terpenes) with potential application as an antiviral or as an insect repellent(e.g. mosquito).
- Fragrances can also be applied to laundry detergents, shampoos, and lotions to provide additional layers of protection against viruses and mosquitoes.

NATURALLY-SOURCED ORIGIN



DEVELOPMENT / IP

- Pilot studies demonstrating protection from insect bites and duration of effect with purely natural and combination compositions.

Composition and Method Patents:

- Insect Repellent; Insect Repellent DB/Expires 2039/2040.
- Infectious diseases (Japan)/Expires Dec 2039.

COMMERCIAL & MARKET POTENTIAL

- Vector-borne diseases account for more than 17% of all infectious disease worldwide: Vector-borne diseases (who.int)

DEVELOPMENT PARTNERS

- **Chemia Corp. St. Louis, MO:** [Chemia Corporation](#)
- Global Manufacturing & Development Partner.
- **Asset available for immediate partnering/out-licensing.**

APPLICATIONS / INDICATION



Antiviral



Insect Repellent



IMPACT BIOMEDICAL, INC.



Laetose™

APPLICATIONS / INDICATION



Sugar Reduction/Substitute



Dietary Supplement



Therapeutics



IMPACT BIOMEDICAL, INC.

Laetose

- Unique combination of multiple sugars independently with inositol, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone.
- Could result in reducing caloric intake and glycemic index in foods.



**BENEFITS OF
INOSITOL
SUPPLEMENTATION**

Sweet
Nutrition

DEVELOPMENT STATUS

- Caloric intake and glycemic index studies planned to support commercial label development.

INTELLECTUAL PROPERTY

- Composition and method patents issued in the US and allowed in Japan, and Russia; pending in European Union and China.
- US Patent: “Low Glycemic Sugar Composition” issued, with expiration 2037.

COMMERCIAL & MARKET POTENTIAL

- U.S. Inflammatory Disease Treatment Market: Estimated \$35B (source: Precedence Research 2022).
- U.S. Refined Sugar Production Market: \$12B (source: Knowledge Sourcing Intelligence).

DEVELOPMENT PARTNERS

- **Asset immediately available for partnering/out-licensing.**



IMPACT BIOMEDICAL, INC.

INTELLECTUAL PROPERTY

PATENTS ISSUED AND PATENTS PENDING

8 Issued U.S. Patents

40+ Patents Pending



Linebacker

3 Patents Issued

9 Patents Pending



3 Patents Issued

13 Patents Pending

3F



1 Patents Issued

26 Patents Pending

Laetose



1 Patents Issued

10 Patents Pending



IMPACT BIOMEDICAL, INC.

WHY INVEST IN IMPACT BIOMEDICAL?



Attractive Valuation/Potential Shareholder Appreciation

Unique Early-Stage Healthcare Company:

- Bio-tech/Med-Tech Regulated
- Consumer (OTC)

Novel Intellectual Property Worldwide:

- Eight (8) Issued Patents
- More than Forty (40) Pending Patents

Potential Near-Term Products Include:

- OTC dietary supplement/prophylactic upper respiratory infections
- Natural Repellents
- Sugar Substitute
- Indoor air quality/purification solutions

Potential Long-Term Products Include:

- Biopharmaceuticals: Oncology, Inflammatory Disease, Neurology

EXECUTIVE OFFICERS



Frank D. Heuszel
CEO



Todd Macko
CFO



Mark Suseck
COO

BOARD OF DIRECTORS

Frank D. Heuszel
Executive Chairman



Frank D. Heuszel has served as President and Director of the Company since August 2020. Since April 2023, Mr. Heuszel has also served as Chief Executive Officer of the Company. Mr. Heuszel has served as the Chief Executive Officer of DSS since April 11, 2019, and has extensive expertise in a wide array of strategic, business, turnaround, and regulatory matters across several industries as a result of his executive management, educational, and operational experience. Prior to joining DSS, Mr. Heuszel had a very successful career in commercial banking and has served as General Counsel, Director of Special Assets, Credit Officer, Chief Financial Officer and Auditor.

Jason Grady



Jason T. Grady serves as the Chief Operating Officer of DSS, Inc., and concurrently holds the position of President at Premier Packaging Corporation, a DSS subsidiary specializing in comprehensive consumer packaging solutions. Jason is also President and COO of DSS Wealth Management, a mutual fund, RIA, and fixed income broker dealer, and President and COO of BioLife Science, Inc., a health and wellness research and discovery company. Jason holds numerous board positions across various companies within the DSS ecosystem and beyond. With a distinguished career spanning over 25 years, Jason is recognized for his adeptness in fostering business expansion and executive leadership, particularly in driving organic growth within multi-divisional companies.

BOARD OF DIRECTORS

Dr. Elise Brownell



Dr. Elise Brownell, Ph.D has served as a director of the Company since January 2021. Dr. Brownell has more than 20 years of biotechnology and pharmaceutical project management experience with a proven track record of advancing programs through clinical development.

She serves as a Life Sciences entrepreneurial advisor for ASTIA, co-founder of ZephyrBiotech, LLC, and was a founding member, head of project management and senior director of Aerovance, Inc., a venture-backed biotechnology company spun out from Bayer Healthcare, where she created and managed effective team processes to bring product candidates into full scale clinical Phase 1 and 2 developments.

Melissa Sims, Esq.



Melissa Sims has served as a director of the Company since May 2023. Ms. Sims is an Illinois licensed attorney having practiced law since 1995. Following graduation from Northern Illinois University College of Law, Ms.

Sims started the general practice of law representing clients in banking, health care, real estate, criminal, dissolution, municipal and probate matters in state and appellate courts. Ms. Sims is an asset to the Board and offers keen insight into matters of importance on behalf of the Company.

BOARD OF DIRECTORS

Castel Hibbert

Castel Hibbert has served as director of the company since September 2023. Mr. Hibbert is originally from Detroit, Michigan and has been in Texas since 1981. He attended Michigan State University where he earned a B.A. degree in Employee Relations and a M.B.A. from the University of Texas-Austin in 1983. He has been involved in corporate banking for 39 years and has held various management, underwriting and line responsibilities. He currently works with upper middle market companies ranging from \$75MM - \$800MM in annual revenues. Castel Hibbert is Executive Vice President and Director in the Commercial Banking Group at Veritex Community Bank. Hibbert has also served on numerous non-profit boards.



David Keene

David Keene has served as director of the company since September 2023. Mr. Keene joined Unity National Bank in September 2022 as the Chief Credit Officer. Mr. Keene has 44 years of commercial banking experience with progressive responsibilities in all areas of community and regional bank environments. Prior to joining Unity, Mr. Keene was Senior Credit Risk Officer at Community Bank of Texas responsible for providing support to the Chief Credit Officer for review and assessment of loans and monitoring of related risks as well as supporting the credit underwriting of high-net-worth individuals, partnerships, and companies. Mr. Keene worked at Patriot Bank as Senior Vice President & Senior Credit Risk Officer with direct responsibility for underwriting, pricing, and loan approval for all loans \$1 million and under, among his other responsibilities He was credit trained at Texas Commerce Bank and has experience in assessing bank loan and portfolio credit quality, loan structuring, and working with loan officers to promote sound credit quality.



BOARD OF DIRECTORS

Chris Zimmerman

Christian Zimmerman is currently the CFO of Keystone Bank, SSB, a community bank located in Austin, Texas. Christian has over 17 years of experience in roles of increasing responsibility in the banking and financial industry, including Controller and CFO for both public and private banks. Prior to entering the banking sector, Christian worked for a national public accounting firm. Christian earned his Bachelor of Business Administration and Master of Public Accounting degrees from The University of Texas at Austin in 2001 and achieved his CPA certification in 2005. Chris and his wife, Sandy, have two young boys, Austin and Zachary.





IMPACT BIOMEDICAL, INC.

www.ImpactBiomedInc.com

FOR MORE INFORMATION CONTACT:

FRANK D. HEUSZEL, President & CEO

fheuszel@impactbiomedinc.com / +1 (281) 415-6576